Hui-Xiong Xu Selected Research

2-(4-toluidino)-6-naphthalenesulfonic acid (TNS)

1/2020	Comparisons of ACR TI-RADS, ATA guidelines, Kwak TI-RADS, and KTA/KSThR guidelines in malignancy risk stratification of thyroid nodules.
1/2019	BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false-positive and false-negative results.
12/2017	A Proposal to Stratify the Intermediate-Risk Thyroid Nodules According to the AACE/ACE/AME Guidelines with Ultrasound Features.
1/2017	Thyroid imaging reporting and data system in assessment of cytological Bethesda Category III thyroid nodules.
1/2017	Cytologically indeterminate thyroid nodules: increased diagnostic performance with combination of US TI-RADS and a new scoring system.
1/2017	Virtual touch tissue imaging and quantification (VTIQ) in the evaluation of thyroid nodules: the associated factors leading to misdiagnosis.
1/2017	Comparison of Virtual Touch Tissue Imaging & Quantification (VTIQ) and Virtual Touch Tissue Quantification (VTQ) for diagnosis of thyroid nodules.
1/2017	First experience of comparisons between two different shear wave speed imaging systems in differentiating malignant from benign thyroid nodules.
1/2017	Comparison of Virtual Touch Tissue Imaging & Quantification (VTIQ) and Toshiba shear wave elastography (T-SWE) in diagnosis of thyroid nodules: Initial experience.
1/2017	Malignancy risk stratification of thyroid nodules: comparisons of four ultrasound Thyroid Imaging Reporting and Data Systems in surgically resected nodules.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hui-Xiong Xu Research Topics

Disease

32	Neoplasms (Cancer) 01/2022 - 06/2003
16	Thyroid Nodule (Nodule, Thyroid) 01/2022 - 01/2016
12	Hepatocellular Carcinoma (Hepatoma) 10/2021 - 11/2005
7	Liver Neoplasms (Liver Cancer) 10/2017 - 11/2003
3	Pain (Aches) 06/2022 - 01/2021
3	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2009
3	Breast Neoplasms (Breast Cancer) 01/2022 - 07/2014
3	Calcinosis 08/2020 - 08/2016
3	Carcinoma (Carcinomatosis) 01/2015 - 06/2008
2	Cystadenocarcinoma 01/2022 - 12/2009
2	Adenoma (Adenomas) 01/2020 - 12/2009
2	Carcinogenesis 01/2017 - 01/2015
2	Cholangiocarcinoma 01/2015 - 01/2006
2	Necrosis 12/2013 - 08/2011
1	Cryptorchidism (Undescended Testes) 06/2022
1	Neurilemmoma (Schwannoma) 01/2022
1	Cough 01/2022
1	Gout 09/2021
1	Cysts 01/2021
1	Graves Disease (Basedow Disease) 01/2021
1	Hemangioma (Angioma) 01/2021
1	Hyperthyroidism 01/2021
1	Follicular Adenocarcinoma 01/2020
1	False Aneurysm (Pseudoaneurysm) 01/2020
1	Papillary Thyroid Cancer 01/2020
1	Thrombosis (Thrombus) 01/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2015
1	Thyroid Neoplasms (Thyroid Cancer) 01/2015
1	Renal Insufficiency (Renal Failure) 01/2014
1	Dysuria 04/2013
1	Leiomyoma (Uterine Fibroids) 07/2010
1	Communicable Diseases (Infectious Diseases) 12/2009
1	Polyps 12/2009
1	Cholecystitis 12/2009
1	Aneurysm (Aneurysms) 12/2009
1	Wounds and Injuries (Trauma) 12/2009
1	Caroli Disease (Caroli's Disease) 12/2009
1	Gallbladder Neoplasms (Gallbladder Cancer) 12/2009
1	Hematoma 12/2009
1	Klatskin Tumor 12/2009
1	Hemorrhage 12/2009
1	Endoleak 12/2009

Drug/Important Bio-Agent (IBA)

10	2-(4-toluidino)-6-naphthalenesulfonic acid (TNS)IBA 01/2020 - 01/2017
3	Capsules (Microcapsules)IBA 08/2020 - 08/2016
3	Contrast MediaIBA 12/2013 - 12/2009
2	Tumor Biomarkers (Tumor Markers)IBA 06/2022 - 01/2015
2	Polidocanol (Laureth)FDA Link 01/2022 - 01/2021
2	Uric Acid (Urate)IBA 09/2021 - 01/2015
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2017 - 07/2014
2	Estrogen ReceptorsIBA 01/2017 - 07/2014
2	human ERBB2 proteinIBA 01/2017 - 07/2014
2	IodineIBA 01/2015 - 01/2014
2	Ethanol (Ethyl Alcohol)IBA 11/2009 - 11/2003
2	contrast agent BR1IBA 06/2008 - 01/2006
1	cupric sulfide (CuS)IBA 01/2022
1	SonazoidIBA 01/2022
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2021
1	Sclerosing Solutions (Sclerosing Agents)IBA 01/2021
1	Antithyroid Agents (Antithyroid Drugs)IBA 01/2021
1	Thrombin FDA Link 01/2020
1	RacivirIBA 01/2020
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2020
1	methylamphotericin B (AME)IBA 12/2017
1	IntegrinsIBA 01/2017
1	Hormones (Hormone)IBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2015
1	Phosphotransferases (Kinase)IBA 01/2015
1	Biological ProductsIBA 01/2015
1	Proto-Oncogene Proteins B-rafIBA 01/2015
1	Therapeutic UsesIBA 01/2014
1	Pharmaceutical PreparationsIBA 12/2013
1	Fetal Proteins (Fetoprotein)IBA 08/2011
1	Hemostatics (Antihemorrhagics)IBA 07/2010
1	CholesterolIBA 12/2009

Therapy/Procedure

15	Radiofrequency Ablation 10/2017 - 11/2003
14	Therapeutics 01/2022 - 06/2003
3	Aftercare (After-Treatment) 01/2022 - 01/2014
2	Sclerotherapy 01/2022 - 01/2021
2	Anesthesia 01/2022 - 11/2015
2	Thyroidectomy 01/2022 - 11/2016
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2022
2	Punctures 01/2020 - 01/2014
2	Electrodes (Electrode) 01/2014 - 11/2003
2	Microbubbles 12/2013 - 06/2008
1	Resuscitation 01/2022
1	General Anesthesia 01/2022
1	Radiotherapy 01/2022
1	Immunotherapy 10/2021
1	Oral Administration 01/2021
1	Length of Stay 01/2021
1	Endovascular Procedures 01/2020
1	Operating Tables 11/2015
1	Cholecystectomy 01/2015
1	Radioimmunotherapy 01/2014
1	Palliative Care (Palliative Therapy) 01/2014
1	Precision Medicine 12/2013
1	Prostatectomy (Retropubic Prostatectomy) 04/2013
1	Hepatectomy 12/2012
1	Contraindications 09/2010
1	High-Intensity Focused Ultrasound Ablation 07/2010